Argenx Se (ARGX) Return on Invested Capital (2017 - 2018)
Argenx Se (ARGX) posted Return on Invested Capital of 0.06% for Q3 2018, down 95.85% on a QoQ basis from 0.03% in Q2 2018, and down 6.0% year-over-year from 0.06% in Q3 2017.
Argenx Se (ARGX) Return on Invested Capital (2017 - 2018) Analysis & Trends
Argenx Se's Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.06% for Q3 2018.
- Quarterly Return on Invested Capital fell 6.0% year-over-year to 0.06% in Q3 2018, while the trailing twelve-month figure through Sep 2018 was 0.06% (down 6.0% YoY) and the FY2017 annual result came in at 0.02%, changed N/A from the prior year.
- Return on Invested Capital was 0.06% for Q3 2018 at Argenx Se, down from 0.03% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.0% in Q3 2017 and bottomed at 0.06% in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -0.06% |
| Jun 30, 2018 | -0.03% |
| Mar 31, 2018 | -0.02% |
| Dec 31, 2017 | -0.02% |
| Sep 30, 2017 | 0.00% |